Hamel Lawrence G 4
4 · ACELRX PHARMACEUTICALS INC · Filed Sep 27, 2017
Insider Transaction Report
Form 4
Hamel Lawrence G
Chief Development Officer
Transactions
- Sale
Common Stock
2017-09-25−13,827→ 68,504 total(indirect: See footnote)
Footnotes (3)
- [F1]52,125 of the Shares are held in the Hamel Revocable Living Trust
- [F2]The Shares were sold in a range from $3.50-$4.50
- [F3]Non-reportable acquisition of 1,977 shares of Common Stock through the Company's Employee Stock Purchase Plan